文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

质子泵抑制剂与组胺2受体拮抗剂使用与胃癌风险:基于人群的队列研究

Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该研究利用韩国国民健康保险数据库,纳入连续使用超过180天累积限定日剂量的PPI或H2RA用户,经倾向评分加权后比较两组胃癌发生率。结果显示,PPI用户与H2RA用户的胃癌发生率无显著差异(调整后HR 1.01,95%CI 0.88-1.16,P=0.89),在胃癌高风险地区长期使用PPI亦未显示更高风险。

要点

  • 长期使用PPI与H2RA的胃癌风险无显著差异。
  • 研究在胃癌高风险地区进行,结果具地域代表性。
  • 敏感性分析支持主要结论的稳健性。

核心结论

  • 长期使用PPI对比H2RA并未增加胃癌风险,即使在胃癌高风险地区亦然。

研究设计与样本

  • 基于韩国国民健康保险服务数据库的人群队列研究,纳入2004至2015年间首次处方PPI或H2RA且食管胃十二指肠镜检查正常者,系统分层随机抽样50%,最终分析长期使用(累积限定日剂量>180天)者,随访至胃癌、非胃癌死亡、胃手术或研究终点(2017年12月)。

主要发现

  • 经倾向评分加权后,纳入39,799名PPI用户和38,967名H2RA用户。
  • PPI组随访182,643人年发现411例新发胃癌,H2RA组随访178,846人年发现397例。
  • 与H2RA用户相比,PPI用户胃癌发生率无显著差异(调整后HR 1.01;95%CI 0.88-1.16;P=0.89)。
  • 敏感性分析证实PPI与H2RA用户间胃癌发生率无差异。

临床怎么用

  • 在临床决策中,长期使用PPI时无需过度担忧胃癌风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Proton pump inhibitors (PPIs) are commonly prescribed medications. Long-term use of PPIs has been suspected to have a provocative effect on gastric cancer. This study was to determine the association between PPI vs histamine 2 receptor antagonist (H2RA) use and the risk of gastric cancer in a region where the risk of this malignancy is high. METHODS: A population-based cohort study using the Korean National Health Insurance Services Database. The participants with first prescription of PPIs and H2RA with normal esophagogastroduodenoscopy finding from 2004 through 2015 were collected. Among them, 50% of participants were systematic stratified randomly sampled. There were 122,118 users of PPIs or H2RAs who use medication more than cumulative defined daily dose of 180 days. The users were followed up from long-term use threshold until gastric cancer, death from non-gastric cancer cause, gastric surgery, or study end (December 2017). RESULTS: After calculating propensity score weights, we included 39,799 PPI and 38,967 H2RA users. Among the new PPI and H2RA users, we identified 411 cases of incident gastric cancer from 182,643 person-years of follow-up observation and 397 cases from 178,846 person-years of follow-up observation, respectively. Compared with H2RA users, PPI users did not experience significantly different gastric cancer incidence (adjusted hazard ratio, 1.01; 95% confidence interval, 0.88-1.16; P = 0.89). Sensitivity analyses confirmed that gastric cancer incidence did not differ between PPI and H2RA users. DISCUSSION: In this large study, long-term treatment with PPIs vs H2RAs did not show higher risk of gastric cancer even in a high-risk region.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shin GY, Park JM, Hong J, et al. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study. Am J Gastroenterol. 2021. PMID: 34074826. doi:10.14309/ajg.0000000000001167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。